Skip to main content

Advertisement

Table 1 Table 1

From: Rupatadine oral solution improves rhino-conjunctive symptoms control in children with 6-11 years weighing ≥25 kg with persistent allergic rhinitis

Mean score reduction Placebo (n=135) Rupatadine (n= 131) P-value
4TSS at 4 weeks -2.4 (1.9) -3.1 (2.1) P < 0.01
4TSS at 6 weeks -2.6( 2.0) -3.4 (2.1) P < 0.01
5TSS at 4 weeks -2.7 (2.4) -3.7 (2.5) P < 0.01
5TSS at 6 weeks -2.9 ( 2.5) -4.0 (2.6) P < 0.01
  1. PRQLQ overall score showed statistical significant differences between RUP and placebo at 4 weeks (p=0.01) and 6 weeks (p<0.05). Adverse events were scarce in both treatment groups throughout the study. Somnolence was reported with a very low incidence (1.4% RUP) and no serious adverse events were reported.